Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
暂无分享,去创建一个
Christopher P Cannon | Michael Miller | E. Braunwald | C. Cannon | S. Murphy | J. Qin | K. Ray | Michael Miller | Kausik K Ray | Sabina A Murphy | Eugene Braunwald | Jie Qin
[1] R. Giugliano,et al. The year in non-ST-segment elevation acute coronary syndrome. , 2005, Journal of the American College of Cardiology.
[2] D. Goff,et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.
[3] Y. Matsuzawa,et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.
[4] J. Danesh,et al. Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.
[5] E. Braunwald,et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. , 2006, European heart journal.
[6] W. Harris,et al. Why do omega-3 fatty acids lower serum triglycerides? , 2006, Current opinion in lipidology.
[7] C. Cannon,et al. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. , 2006, Journal of the American College of Cardiology.
[8] R. Giugliano,et al. The year in non-ST-segment elevation acute coronary syndromes. , 2006, Journal of the American College of Cardiology.
[9] Nader Rifai,et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.
[10] E. Braunwald,et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.
[11] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[12] K. Yano,et al. Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence?: The Honolulu Heart Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[13] P. Ridker,et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.
[14] B. G. Brown. Can niacin slow the development of atherosclerosis in coronary artery disease patients already taking statins? , 2005, Nature Clinical Practice Cardiovascular Medicine.
[15] B. Cohen,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[16] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[17] M. Serio,et al. Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity , 2004, Journal of endocrinological investigation.
[18] C. Cannon,et al. Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation , 2004, Journal of Thrombosis and Thrombolysis.
[19] M. Linton,et al. The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy , 2004, Current atherosclerosis reports.
[20] T. Lam,et al. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. , 2004, Annals of epidemiology.
[21] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[22] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[23] S. Shieh,et al. Thrombophilia in Patients with Hypertriglyceridemia , 2004, Journal of Thrombosis and Thrombolysis.
[24] A. Miller. Some concerns about the future of the practice of cardiovascular medicine , 2003, Clinical cardiology.
[25] B. Binder,et al. Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[26] J. Larosa. Understanding risk in hypercholesterolemia , 2003, Clinical cardiology.
[27] F. Sacks,et al. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. , 2002, The American journal of medicine.
[28] R. Morton,et al. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport DOI 10.1194/jlr.M100431-JLR200 , 2002, Journal of Lipid Research.
[29] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[30] MonicaGomaraschi,et al. Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol , 2002 .
[31] E. Braunwald,et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.
[32] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[33] C. Ballantyne,et al. The evolving role of high-density lipoprotein in reducing cardiovascular risk. , 2001, Preventive cardiology.
[34] G. Assmann. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. , 2001 .
[35] R. Morton,et al. Elevated Triglyceride Content Diminishes the Capacity of High Density Lipoprotein to Deliver Cholesteryl Esters via the Scavenger Receptor Class B Type I (SR-BI)* , 2001, The Journal of Biological Chemistry.
[36] Jiang He,et al. Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials , 2000 .
[37] K. Parhofer,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Atorvastatin Improves Postprandial Lipoprotein Metabolism in Normolipidemic Subjects* , 2022 .
[38] M. Miller,et al. Current perspectives on the management of hypertriglyceridemia. , 2000, American heart journal.
[39] A. Gotto,et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. , 1999, Circulation.
[40] A. Seidler,et al. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. , 1998, Journal of the American College of Cardiology.
[41] J. Buring,et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. , 1997, Circulation.
[42] P. Wilson,et al. Familial lipoprotein disorders and premature coronary artery disease. , 1994, Atherosclerosis.
[43] A. Hamsten,et al. Postprandial lipoproteins and progression of coronary atherosclerosis. , 1994, Atherosclerosis.
[44] E. Schaefer,et al. Familial lipoprotein disorders and premature coronary artery disease. , 1993, The Medical clinics of North America.
[45] D. Jacobs,et al. Plasma triglyceride level and mortality from coronary heart disease. , 1993, The New England journal of medicine.
[46] L. Tenkanen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study , 1992 .
[47] Vesa Manninen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.
[48] M. King,et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.
[49] J L Witztum,et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.
[50] T. Meade,et al. HYPERTRIGLYCERIDAEMIA AND HYPERCOAGULABILITY , 1983, The Lancet.
[51] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.